Pharmacologic reversal of anticoagulants relies on specific antidotes like idarucizumab and andexanet alfa, though challenges remain regarding dosing, monitoring, and thrombotic risk mitigation.
This review provides a comprehensive overview of current pharmacologic reversal strategies for anticoagulants, highlighting specific antidotes and ongoing clinical challenges such as dosing, monitoring, and thrombotic risk mitigation.
The global rise in anticoagulant use has increased the number of major bleeding events that warrant timely and effective pharmacologic reversal. Reversal strategies should be informed by the pharmacodynamic and pharmacokinetic features of the anticoagulant and antidote, regulatory indications, quality of evidence, patient-specific factors, and availability of treatment options. Protamine sulfate neutralizes unfractionated heparin, whereas no specific antidotes exist for low-molecular-weight heparins or fondaparinux. Four-factor prothrombin complex concentrates effectively reverse vitamin K antagonists. Idarucizumab specifically reverses dabigatran, although delayed dabigatran rebound can occur. Andexanet alfa targets direct oral factor Xa inhibitors, but uncertainties regarding the efficacy-safety balance, monitoring, rebound, perioperative use, and cost have prompted off-label use of four-factor prothrombin complex concentrates, for which stronger evidence is needed. Key challenges remain, including determination of appropriate dosing, standardization and validation of laboratory monitoring, mitigation of thrombotic risk, and development of guidelines for perioperative treatment. Emerging agents aim to broaden targets and improve safety. Building high-quality evidence remains essential to advancing global, patient-centered anticoagulant and hemostatic care.
“There is no [single] optimal approach. The effective and safe approach to [managing] patients who bleed under DOACs always has to consider surgery- and patient-specific factors.”
Rocca et al. (2026) conducted a review in Major bleeding events requiring anticoagulation reversal. Antidotes for anticoagulation reversal was evaluated. Pharmacologic reversal of anticoagulants relies on specific antidotes like idarucizumab and andexanet alfa, though challenges remain regarding dosing, monitoring, and thrombotic risk mitigation.